Please assess the completion status of the following clinical trial:

Trial Title: Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion For subjects with diabetic nephropathy,~1. Adults (ages 40 - 75 years)~2. Diagnosis of type 2 diabetes for more than 5 years~3. Evidence of diabetic nephropathy as evidenced by~   a. More than 150 mg of proteinuria per day in a 24-hour urine collection, or a spot morning urine protein to creatinine of greater than 0.15, or a spot morning urine albumin to creatinine ratio greater than 100 confirmed on two separate occasions within 12 months~4. Treatment with a blocker of the renin -angiotensin-aldosterone system (either ACE inhibitor or ARB)~For healthy controls,~1. Adults (ages 40 - 75 years)~2. Good general health~Exclusion For subjects with diabetic nephropathy,~1. Type 1 diabetes~2. Glomerular filtration rate less than 40 ml/min/1.73 m2 by MDRD formula~3. Hemoglobin A1C greater than 10%~4. Blood pressure greater than 150/90 mm Hg or less than 100/55 mm Hg~5. History of kidney transplantation~6. Oxygen saturation is less than 80%~7. History of unstable cardiopulmonary conditions, known intracardiac shunts, or pulmonary hypertension~8. History of active cancer within the last 3 years~For healthy controls,~1. History or clinical evidence of any chronic disease~2. Chronic and regular use of any medications except for oral contraceptives and vitamins~3. Clinically significant abnormal screening laboratory values~4. Pregnancy or lactation for women~5. Blood pressure at screening visit less than 110/60~6. History of unstable cardiopulmonary conditions, known intracardiac shunts, or pulmonary hypertension~7. History of active cancer within the last 3 years

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with diabetic nephropathy (Type: EXPERIMENTAL): Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
- Healthy volunteers (Type: ACTIVE_COMPARATOR): Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

Based on this trial design, predict the completion outcome and termination type (if applicable).